If you’re going to develop an orphan drug, you’re going to have to charge a substantial price for the drug in order to make it worthwhile.

It could be huge, … potentially a multi-billion dollar drug.

This is reminiscent of a period about five years ago when (National Basketball Association star) Magic Johnson got AIDS and any company with anything to do with AIDS research went up, … Those companies that...

The new data adds $100 million to $150 million on top of that projection [that sales would double] because even though there’s less efficacy, it’s less toxic to heart patients,

(The wet AMD market) is already pretty big. There are treatments, but this looks like a positive step,

We think it’s a great stock, … But we can’t say that the stock is cheap, trading at over 80 times earnings. We get a little bit of acrophobia.

My first take on it was that I was concerned about dilution to Amgen,